IUPAC/Chemical Name
2-((5-(2-(phenylsulfonamido)ethyl)thiophen-2-yl)oxy)acetic acid
InChi Key
ISSKMEQROMFEHL-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H15NO5S2/c16-13(17)10-20-14-7-6-11(21-14)8-9-15-22(18,19)12-4-2-1-3-5-12/h1-7,15H,8-10H2,(H,16,17)
SMILES Code
O=C(O)COC1=CC=C(CCNS(=O)(C2=CC=CC=C2)=O)S1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
341.39
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Sadjak A, Supanz S, Fellier H. Determination of efficacy of linotroban by inducing a reduction of renal inulin/para-aminohippuric acid clearances with the thromboxane A2 mimetic U-46619 in the conscious female rat. Arzneimittelforschung. 2000 Sep;50(9):816-20. PubMed PMID: 11050698.
2: Dorner GT, Pehamberger H, Kornek G, Steger G, Müller M, Wolzt M, Kletter K, James P, Breiteneder H, Eichler HG, Blöchl-Daum B. Cisplatin-induced renal effects and thromboxane A2 receptor blockade. Eur J Clin Invest. 1997 Oct;27(10):836-9. PubMed PMID: 9373762.
3: Supanz S, Sadjak A, Fellier H, Eidenberger T. Effects of the novel thromboxane (TXA2) receptor antagonist linotroban on inulin and para-aminohippuric acid clearances in the conscious male and female rat. Arzneimittelforschung. 1997 Sep;47(9):1026-30. PubMed PMID: 9342416.
4: Li GA, Wang X, Meng X, Lin YB, Li X, Liu XJ. [Design, synthesis of novel N, N'-bis-(halogenophenyl)-4- methoxybenzene-1, 3-disulfonamides and evaluation of their anti-platelet aggregation activity]. Yao Xue Xue Bao. 2015 Feb;50(2):185-90. Chinese. PubMed PMID: 25975026.
5: Sakariassen KS, Orning L, Stormorken H. Role of ADP and thromboxanes in human thrombus formation in ex vivo models. Platelets. 1997;8(6):385-90. PubMed PMID: 16793672.
6: Gasic S, Eichler HG, Kyrle PA, Wolzt M, Eidenberger T, Vierhapper H. Thromboxane A2 does not mediate angiotensin II-dependent nonischemic peripheral vasoconstriction in healthy men: a pilot study. Int J Clin Pharmacol Ther. 1997 Feb;35(2):56-60. PubMed PMID: 9147708.
7: Roald HE, Barstad RM, Engen A, Kierulf P, Skjørten F, Sakariassen KS. HN-11500--a novel thromboxane A2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions. Thromb Haemost. 1994 Jan;71(1):103-9. PubMed PMID: 8165627.
